LLY Archives

I drug discovery display with molecular structures on a skyscraper near Wall Street, above green market graphics and overlooking business professionals at dusk

Iambic’s $150 Million IPO Puts AI Drug Discovery in Wall Street’s Spotlight -( $IAM $IBB $JNJ $LLY $NVDA $TAK $XBI )

by John F. Heerdink, Jr. October 12, 2026 587Views 0Likes

Nvidia-backed biotech pairs a clinical-stage cancer pipeline with pharmaceutical partnerships as TRex Bio, Retension and Lycia join the IPO queue October 8, 2026 Artificial intelligence has spent the past several years promising to transform drug discovery. Iambic Therapeutics is now asking Wall…

October 9, 2026 weekly market summary illustration showing rising stock charts, AI servers, and declining consumer sentiment bars

Weekly Market Summary (Friday, October 9, 2026): Stocks Close Higher as AI Rebounds and Consumer Sentiment Weakens -( $AMWL $DAL $DOCS $EPRX $LITE $LLY $LPL $MODD $MRNA $NVDA $SER $TSLA $YSG )

by John F. Heerdink, Jr. October 9, 2026 157807Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Open walnut jewelry box with blue velvet compartments holding smart rings, a gold upward-trending market arrow, and a newspaper referencing Oura’s public debut.

Oura IPO Signals That Preventive Health Has Found Its Jewelry Box -( $AAPL $GOOGL $OURA $LLY )

by John F. Heerdink, Jr. September 22, 2026 294Views 0Likes

Oura’s proposed Nasdaq debut under OURA is shaping up as more than another wearable-device listing. It is a high-growth health-intelligence story built around a deceptively simple object: a screenless ring that turns sleep, stress, activity, heart health, metabolic health, and women’s health data into…

Amylyx Ignites a New GLP-1 Investment Narrative as Clinical Data, Pharmacy Access and Diabetes Innovation Converge -( $AMLX $CVS $LLY $MODD $NVO )

by John F. Heerdink, Jr. August 18, 2026 413Views 0Likes

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…

Tag: LLY

Iambic’s $150 Million IPO Puts AI Drug Discovery in Wall Street’s Spotlight -( $IAM $IBB $JNJ $LLY $NVDA $TAK $XBI )

Weekly Market Summary (Friday, October 9, 2026): Stocks Close Higher as AI Rebounds and Consumer Sentiment Weakens -( $AMWL $DAL $DOCS $EPRX $LITE $LLY $LPL $MODD $MRNA $NVDA $SER $TSLA $YSG )

Oura IPO Signals That Preventive Health Has Found Its Jewelry Box -( $AAPL $GOOGL $OURA $LLY )

Amylyx Ignites a New GLP-1 Investment Narrative as Clinical Data, Pharmacy Access and Diabetes Innovation Converge -( $AMLX $CVS $LLY $MODD $NVO )

Your Guide To Staying Informed In The Markets